Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social | Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
|
File:Phendimetrazine.png | |
| 3,4-Dimethyl-2-phenyl-morpholine IUPAC name | |
| CAS number 634-03-7 |
ATC code |
| PubChem 12460 |
DrugBank |
| Chemical formula | |
| Molecular weight | 191.27 |
| Bioavailability | Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours |
| Metabolism | hepatic |
| Elimination half-life | 19-24 hours |
| Excretion | Urinary elimination |
| Pregnancy category | C (US) |
| Legal status | C-III (US) |
| Routes of administration | Oral |
| Indicated for: |
Phendimetrazine (Bontril®) is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule III controlled substance under the Uniform Controlled Substances Act of 1970.
Phendimetrazine is used clinically in the form of phendimetrazine tartrate.
Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction.
According to the "List of psychotropic substances under international control," phendimetrazine is a Schedule IV controlled substance.[How to reference and link to summary or text]
External links[]
| This page uses Creative Commons Licensed content from Wikipedia (view authors). |